Cancer Chemotherapy and Pharmacology

, Volume 49, Issue 2, pp 149–154

PEG-asparaginase (Oncaspar) 2500 U/m2 BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols

  • Hans-Joachim Müller
  • Rita Beier
  • João da Palma
  • Claudia Lanvers
  • Elvira Ahlke
  • Volker von Schütz
  • Martin Gunkel
  • Alexander Horn
  • Martin Schrappe
  • Günter Henze
  • Karen Kranz
  • Joachim Boos
Original Article

DOI: 10.1007/s00280-001-0391-5

Cite this article as:
Müller, HJ., Beier, R., da Palma, J. et al. Cancer Chemother Pharmacol (2002) 49: 149. doi:10.1007/s00280-001-0391-5

Abstract.

Purpose: As previous data had shown that only two-thirds of patients had the predicted activity time courses when PEG-asparaginase 1000 U/m2 was used in reinduction after native E. coli asparaginase in induction treatment of acute lymphoblastic leukaemia (ALL), drug monitoring was performed with the use of a higher dose. Methods: Because one-third of patients had insufficient serum asparaginase activity time courses after a single dose of 1000 U/m2 PEG-asparaginase during reinduction treatment, a dose of 2500 U/m2 PEG-asparaginase, which is the approved dosage in Germany, was used in 39 reinduction and 20 relapse patients to determine whether prolongation of the activity time course may be possible with this higher dose, and to look for significant differences between reinduction and relapse patients. Results: After 1, 2 and 3 weeks, the mean activities were 1113±699 U/l, 231±259 U/l, and 13±35 U/l in the reinduction patients, and 1078±649 U/l, 165±195 U/l and 19±28 U/l in the relapse patients, respectively. There were a considerable number of patients with a substantially shortened activity time course in both groups. In 10 of 39 reinduction patients and in 7 of 24 doses during relapse treatment, only activities <100 U/l were found after 1 week with a further fast decline. No statistically significant differences between the two patient groups could be shown at any time-point. Conclusions: Comparison of these data with activities after 1000 U/m2 PEG-asparaginase showed no prolongation of the time with activity in the therapeutic range with the higher dose. Therefore, for a longer duration of therapeutic activity, administration of further doses is mandatory.

PEG asparaginase Pharmacokinetics Reinduction Relapse Acute lymphoblastic leukaemia 

Copyright information

© Springer-Verlag 2001

Authors and Affiliations

  • Hans-Joachim Müller
    • 1
  • Rita Beier
    • 2
  • João da Palma
    • 3
  • Claudia Lanvers
    • 1
  • Elvira Ahlke
    • 1
  • Volker von Schütz
    • 4
  • Martin Gunkel
    • 5
  • Alexander Horn
    • 6
  • Martin Schrappe
    • 2
  • Günter Henze
    • 3
  • Karen Kranz
    • 1
  • Joachim Boos
    • 1
  1. 1.Department of Pediatric Hematology/Oncology, University of Münster, Albert-Schweitzer-Strasse 33, 48149 Münster, GermanyGermany
  2. 2.Department of Pediatric Hematology/Oncology, Medical School Hanover (ALL-BFM Study Center), Carl-Neuberg-Strasse 1, 30625 Hannover, GermanyGermany
  3. 3.Department of Pediatric Hematology/Oncology, Charité Campus Virchow Klinikum Berlin (ALL-BFM Relapse Study Center), Augustenburger Platz 1, 13353 Berlin, GermanyGermany
  4. 4.Department of Pediatric Hematology/Oncology, University of Essen, Hufelandstrasse 55, 45122 Essen, GermanyGermany
  5. 5.Department of Pediatric Hematology/Oncology, University of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, GermanyGermany
  6. 6.MedacSchering Onkologie GmbH, Nördliche Auffahrtsallee 44, 80638 Munich, GermanyGermany
  7. 7.Present address: Philipps-Universität Marburg, Institut für Physiologische Chemie, Karl-von-Frisch-Strasse 1, 35033 Marburg, Germany, e-mail: muellerb@mailer.uni-marburg.de, Tel.: +49-6421-2862291, Fax: +49-6421-2864335Germany

Personalised recommendations